ClinicalTrials.gg
TerminatedNCT01126749Updated Feb 28, 2022Results posted

Eribulin Mesylate Administered in Combination With Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Alone as First-Line Therapy for Locally Advanced or Metastatic Bladder Cancer

A Phase 1/2 interventional study of Gemcitabine and E7389 in Bladder Cancer, sponsored by Eisai Inc.. Terminated at 42 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-02-28.

Sponsored by Eisai Inc. · Phase 1/2, Interventional, and Treatment

Why this study was terminated
Study was terminated as per sponsor's decision

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
92
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 101 studies testing gemcitabine in Urinary Bladder Neoplasms — 12 open to participants now, 23 under way, 3 of them phase 3. Gemcitabine · Urinary Bladder Neoplasms.

Enrollment
21st of 96
92 · median 42
Started
2010
with 1 other
Phase 1/2
11 of 101
1 open now
Registered
50th of 101
by date

Among the 101 studies testing gemcitabine in Urinary Bladder Neoplasms, this one is the 21st largest by enrollment of the 96 interventional ones that give a count, is one of 2 that started in 2010, is one of 11 in phase 1/2, and was the 50th registered.

Urinary Bladder Neoplasms

1,800 studies on the registry are indexed under Urinary Bladder Neoplasms; 446 are open to participants now.

Browse Urinary Bladder Neoplasms studies →

Open to participants now

12 of the 101 studies testing gemcitabine in Urinary Bladder Neoplasms are open now, in 5 countries. Recruiting first, the newest first:

7 more — sign in →

By country, each count listing its studies:

All 12 open studies →

About gemcitabine

Gemcitabine: first FDA approval 1996 (GEMZAR). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 336 Urinary Bladder Neoplasms studies recruiting now, 256 (76%) set no upper age limit and 22 (7%) stop at 75 or younger; 22 take children under 18; 21 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 101 studies testing gemcitabine in Urinary Bladder Neoplasms, or all of them as a file.
02

Study summary

The purpose of this study is to determine whether Patients with Locally Advanced or Metastatic Bladder Cancer who receive Eribulin Mesylate Administered in Combination with Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Alone as First-Line Therapy is safety and tolerable when administered to patients with locally advanced or metastatic bladder cancer and to gain preliminary data on whether patients may benefit from this combination.

Read the detailed description

This open-label, multicenter, randomized study will consist of 2 phases:

  • Phase Ib: a safety run-in period with 3 ascending doses of eribulin;
  • Phase II: a randomized 2-arm design. Phase Ib Patients will be recruited into cohorts, with a minimum of 3 and a maximum of 6 patients per cohort. All patients will receive the same dose of gemcitabine (1000 mg/m2 on Days 1 and 8 of a 21-day cycle) and cisplatin (70 mg/m2 on Day 1) in combination with eribulin (administered on Days 1 and 8 of the cycle). All patients in a cohort will receive the same dose level of eribulin.

The dose level of eribulin will be escalated for additional cohorts unless greater than 2 dose limiting toxicities (DLTs) are reported at the lower dose level(s) prior to enrollment of the next dose level. If one DLT occurs at any dose level, the cohort will be expanded to include up to a maximum of 6 patients.

A Dose Escalation Committee will determine when no further dose escalation is appropriate and whether the MTD will be defined as a preceding dose or an intermediate dose.

Phase II Patients will be randomized in a 1:1 ratio to receive either eribulin in combination with gemcitabine plus cisplatin (Arm 1) or gemcitabine plus cisplatin alone (Arm 2). The eribulin dose will be 1.0 mg/m2 administered on Days 1 and 8 of each 21-day treatment cycle, the recommended Phase II dose for eribulin when administered in combination gemcitabine plus cisplatin, as determined in the Phase Ib portion of the study.

Allocation of patients will be stratified based on metastatic disease status (patients with visceral metastases versus patients with non-visceral metastases). This stratified randomization will be centrally allocated across all centers via an Interactive Voice Activated Response System (IVRS).

For both the Phase Ib and Phase II portions, 1 cycle of therapy will last 21 days, with a maximum number of 6 gemcitabine plus cisplatin cycles. Radiologic examinations including a computed tomography (CT) scan of the chest, abdomen, and pelvis as appropriate (and CT or magnetic resonance imaging [MRI] scan as appropriate), will be performed during Screening and after every 6 weeks while on therapy. In the case of dose delays, scans should be performed according to the original Cycle 1 Day 1 schedule (ie, scans should not be delayed). Radiographic assessments should be repeated at withdrawal if the last assessment was obtained greater than 3 weeks from withdrawal of therapy. Patients will be followed until death following completion of therapy. Scans will be required every 2 months until documentation of PD or the start of a next line of therapy, whichever occurs first. In patients experiencing PD, follow-up will be for survival only and radiographic scans are not required.

03

Conditions studied

  • Bladder Cancer

Keywords

  • Locally Advanced or Metastatic Bladder Cancer, including other transitional cell cancers of the urothelium (prostate, urethra, ureter, and renal pelvis)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patients may be entered in the study only if they meet all of the following criteria:

  1. Male or female patient greater than 18 years of age;
  2. or cytologically confirmed, locally advanced Stage 4 (eg, T4b) or transitional cell cancer of the bladder; including other transitional cell cancers of the urothelium (prostate, urethra, ureter, and renal pelvis)
  3. Not previously treated with systemic chemotherapy for metastatic bladder cancer (one regimen of or neoadjuvant chemotherapy is permitted). Patients must have a disease-free interval of 6 months after adjuvant therapy;
  4. At least 1 site of by the version 1.1 (RECIST version 1.1) guidelines;
  5. of greater than or equal to 3 months;
  6. (ECOG) Performance Status (PS) 0 or 1;
  7. Patients must have active bowel function defined as at least 3 bowel movements per week according to subject history and must be willing to maintain a diary of bowel function prior to dosing and continuing through completion of study treatment. Laxatives may be used to maintain adequate bowel function;
  8. Patients must have adequate renal function as evidenced by calculated greater than or equal to 55 mL/min per the Cockcroft and Gault formula;
  9. Patients must have adequate bone marrow function as evidenced by (ANC) greater than or equal to 1.5 x 10\^9/L, greater than or equal to 10.0 g/dL (a hemoglobin less than 10.0 g/dL at Screening is acceptable if it is corrected to greater than or equal to 10.0 g/dL by growth factor or transfusion prior to first dose), and count greater than or equal to 100 x 10\^9/L;
  10. Patients must have adequate liver function as evidenced by less than or equal to 1.5 times the (ULN), and alkaline phosphatase, (ALT), and aspartate aminotransferase (AST) less than or equal to 3 x ULN (in the case of liver metastases, less than or equal to 5 x ULN). If there are bone metastases, liver-specific alkaline phosphatase may be separated from the total and used to assess liver function instead of total alkaline phosphatase;
  11. Male or female patients of child-producing potential must agree to use double barrier , oral contraceptives, or avoidance of pregnancy measures during the study and for 90 days after the last day of treatment;
  12. Females of must have a negative serum pregnancy test at screening;
  13. Females may not be breastfeeding;
  14. Ability to understand and willingness to sign a written .

Exclusion criteria

Exclusion Criteria

Patients will not be entered in the study for any of the following reasons:

  1. Prior treatment with epothilone, ixabepilone, patupilone, vinflunine, halichondrin B, and/or halichondrin B chemical derivatives;
  2. History of other except: (1) adequately treated basal or squamous cell carcinoma of the skin; (2) curatively treated, a) in situ carcinoma of the uterine cervix, or b) prostate cancer, or c) superficial bladder cancer; or (3) other curatively treated solid tumor with no evidence of disease for greater than or equal to 3 years;
  3. Presence of , unless the patient has received adequate treatment at least 4 weeks prior to randomization, and is stable, asymptomatic, and off for at least 4 weeks prior to randomization;
  4. Received an agent, chemotherapy, biological therapy, hormonal therapy, targeted therapy, or radiotherapy within 30 days prior to commencing study treatment, or have not recovered from all treatment-related toxicities to Common Toxicity Criteria (CTC) Grade less than or equal to 1, except for alopecia;
  5. Are currently receiving an investigational agent or any other systemic anticancer treatment, including palliative radiotherapy;
  6. Significant cardiovascular impairment (history of congestive heart failure [NYHA] Grade greater than 2, unstable angina or myocardial infarction within the past 6 months, or serious cardiac arrhythmia);
  7. Subjects with a high probability of Long Syndrome;
  8. Patients with organ allografts requiring ;
  9. Known active infection with (HIV), , virus (HBV) or ; virus (HCV);
  10. to halichondrin B and/or halichondrin B chemical derivative
  11. Prior pelvic radiation;
  12. History of known or suspected peritoneal carcinomatosis with risk of bleeding or perforation, or intraluminal or serosal lesions with risk of bleeding or perforation of any lesions;
  13. History of abdominal adhesions, fistula, diverticulitis, gastrointestinal perforation, intra-abdominal abscess, documented peptic ulcer disease (active gastroesophageal reflux disease/dyspepsia are allowed), or other gastrointestinal conditions with increased risk of perforation;
  14. , version 4.0 (CTCAE v.4.0) Grade greater than or equal to 2 constipation;
  15. CTCAE v.4.0 Grade greater than or equal to 2 peripheral neuropathy;
  16. Have any medical condition that would interfere with the conduct of the study.
Terms in these criteria, in plain language(29)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
92 participants (actual)

Study arms

  • Experimental
    E7389 in combination with gemcitabine plus cisplatin

    Drug: Gemcitabine · Drug: E7389 · Drug: Cisplatin

  • Experimental
    gemcitabine plus cisplatin

    Drug: Gemcitabine · Drug: Cisplatin

Interventions

06

What researchers measure

Primary outcomes

  1. Phase 1b: Number of Participants With Dose-limiting Toxicity (DLT) as Per National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 4.0

    DLTs were clinically significant adverse events within 21 days of treatment judged by investigator at least possibly related to treatment. This included greater than or equal to (\>=) Grade 3 (G3) peripheral neuropathy, \>=G3 nausea and vomiting despite optimal anti-emetic treatment, any other non-hematologic toxicity of \>=G3 (except alopecia, single abnormal laboratory values the Investigator judged unlikely related to study therapy, had no clinical correlate, and resolved within 7 days, and hypersensitivity reaction to any of the compounds), Grade 4 neutropenia lasting over 7 days, febrile neutropenia (defined as fever \>=38.5 degrees Celsius with absolute neutrophil count below 1.0\*10\^9 per liter, G3 thrombocytopenia with nontraumatic bleeding (without therapeutic systemic anticoagulation) requiring platelet transfusion, Grade 4 thrombocytopenia (with or without nontraumatic bleeding), any study drug-related death, any other toxicity the dose escalation committee believed to be DLT.

    Time frame: Cycle 1 (Cycle length=21 days)

  2. Phase 2: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

    TEAE was defined as an adverse event that had an onset date, or a worsening in severity on or after the first dose of study drug up to the end of the study. Number of participants with TEAEs were reported based on safety assessments of laboratory tests, physical examination, examining bowel movements, regular measurement of vital signs, eastern cooperative oncology group-performance status and electrocardiogram parameter values. SAE was any untoward medical occurrence that at any dose: resulted in death; life threatening required inpatient hospitalization; resulted in persistent, significant disability; was congenital anomaly/birth defect or medically important due to other reasons than mentioned criteria. Number of participants with TEAEs and SAEs were reported.

    Time frame: From the first dose of study drug up to approximately 6 years 3 months

Secondary outcomes

  1. Phase 2: Progression-free Survival (PFS)

    PFS was defined as the time from the date of randomization until the earlier of the following two events: the date of disease progression (PD) or the date of death based on response evaluation criteria in solid tumor (RECIST) version (v) 1.1. PD was defined as at least a 20 percent (%) increase or 5 millimeter (mm) increase in the sum of diameters of target lesions (taking as reference the smallest sum on study) recorded since the treatment started or the appearance of 1 or more new lesions.

    Time frame: From the date of randomization until the earlier of the following two events: the date of PD or the date of death (Up to approximately 6 years 3 months)

  2. Phase 2: Percentage of Participants With Overall Response

    Overall response rate was defined as the percentage of participants with the best confirmed response of complete response (CR) or partial response (PR) based on RECIST v1.1. CR was defined as complete disappearance of all target lesions. Any pathological lymph nodes (whether target or nontarget) must have reduction in short axis to less than 10 mm. PR was defined as at least a 30% decrease in the sum of the longest diameters of target lesions, taking as reference the baseline summed longest diameters.

    Time frame: From the date of randomization until CR or PR (Up to approximately 6 years 3 months)

  3. Phase 2: Percentage of Participants With Progression-free Survival at Week 12

    PFS was defined as the time from the date of randomization until the earlier of the following two events: the date of PD or the date of death based on RECIST v1.1. PD was defined as at least a 20% increase or 5 mm increase in the sum of diameters of target lesions (taking as reference the smallest sum on study) recorded since the treatment started or the appearance of 1 or more new lesions.

    Time frame: Week 12

  4. Phase 2: Time to Progression (TTP)

    TTP was defined as the time from the date of randomization until the date of PD based on RECIST v1.1. PD was defined as at least a 20% increase in the sum of the longest diameters of target lesions, taking in reference the smallest summed longest diameters on study (this included the baseline sum if that was the smallest on study). In addition to the relative increase of 20%, the sum must also have demonstrated an absolute increase of at least 5 mm. The appearance of 1 or more new lesions was also considered progression.

    Time frame: From the date of randomization until the date of PD (Up to approximately 6 years 3 months)

  5. Phase 2: Overall Survival (OS)

    OS was defined as the time from the date of randomization until the date of death due to any cause.

    Time frame: From the date of randomization until the date of death (Up to approximately 6 years 3 months)

07

Results

Posted Feb 28, 2022
Limitations and caveats
Due to the lack of a clear definition for PFS censoring rules and deviation from the statistical analysis plan relating to interim analyses, the PFS analysis was deemed unreliable and therefore data was not collected and reported.

Participant flow

Participants took part in the study at 32 investigative sites in Germany, Netherlands, Spain, Ukraine, United Kingdom and the United States from 16 April 2010 to 20 July 2016.

Phase 1b
Participant flow — Phase 1b
MilestonePhase 1b: Eribulin Mesylate 0.7 mg/m^2 + Gemcitabine 1000 mg/m^2 + Cisplatin 70 mg/m^2Phase 1b: Eribulin Mesylate 1.0 mg/m^2 + Gemcitabine 1000 mg/m^2 + Cisplatin 70 mg/m^2Phase 2: Eribulin Mesylate 1.0 mg/m^2 + Gemcitabine 1000 mg/m^2 + Cisplatin 70 mg/m^2Phase 2: Gemcitabine 1000 mg/m^2 + Cisplatin 70 mg/m^2
Started3600
Completed0000
Not completed3600
Withdrew: Other0100
Withdrew: Withdrawal by subject0100
Withdrew: Death3400
Phase 2
Participant flow — Phase 2
MilestonePhase 1b: Eribulin Mesylate 0.7 mg/m^2 + Gemcitabine 1000 mg/m^2 + Cisplatin 70 mg/m^2Phase 1b: Eribulin Mesylate 1.0 mg/m^2 + Gemcitabine 1000 mg/m^2 + Cisplatin 70 mg/m^2Phase 2: Eribulin Mesylate 1.0 mg/m^2 + Gemcitabine 1000 mg/m^2 + Cisplatin 70 mg/m^2Phase 2: Gemcitabine 1000 mg/m^2 + Cisplatin 70 mg/m^2
Started004241
Safety analysis set (sas)/treated004139
Modified-intent-to-treat (mitt)004039
Completed0000
Not completed004241
Withdrew: Completed 1 year follow-up per protocol0047
Withdrew: Study termination by sponsor00126
Withdrew: Other0042
Withdrew: Withdrawal by subject0002
Withdrew: Lost to follow-up0001
Withdrew: Death002222
Withdrew: Adverse event0001

Outcome measures

PrimaryPhase 1b: Number of Participants With Dose-limiting Toxicity (DLT) as Per National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 4.0

DLTs were clinically significant adverse events within 21 days of treatment judged by investigator at least possibly related to treatment. This included greater than or equal to (\>=) Grade 3 (G3) peripheral neuropathy, \>=G3 nausea and vomiting despite optimal anti-emetic treatment, any other non-hematologic toxicity of \>=G3 (except alopecia, single abnormal laboratory values the Investigator judged unlikely related to study therapy, had no clinical correlate, and resolved within 7 days, and hypersensitivity reaction to any of the compounds), Grade 4 neutropenia lasting over 7 days, febrile neutropenia (defined as fever \>=38.5 degrees Celsius with absolute neutrophil count below 1.0\*10\^9 per liter, G3 thrombocytopenia with nontraumatic bleeding (without therapeutic systemic anticoagulation) requiring platelet transfusion, Grade 4 thrombocytopenia (with or without nontraumatic bleeding), any study drug-related death, any other toxicity the dose escalation committee believed to be DLT.

Time frame:
Cycle 1 (Cycle length=21 days)
Reported as:
Count of participants · Participants
Phase 1b: Number of Participants With Dose-limiting Toxicity (DLT) as Per National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 4.0
ParticipantsPhase 1b: Eribulin Mesylate 0.7 mg/m^2 + Gemcitabine 1000 mg/m^2 + Cisplatin 70 mg/m^2Phase 1b: Eribulin Mesylate 1.0 mg/m^2 + Gemcitabine 1000 mg/m^2 + Cisplatin 70 mg/m^2
Phase 1b: Number of Participants With Dose-limiting Toxicity (DLT) as Per National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 4.001
PrimaryPhase 2: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

TEAE was defined as an adverse event that had an onset date, or a worsening in severity on or after the first dose of study drug up to the end of the study. Number of participants with TEAEs were reported based on safety assessments of laboratory tests, physical examination, examining bowel movements, regular measurement of vital signs, eastern cooperative oncology group-performance status and electrocardiogram parameter values. SAE was any untoward medical occurrence that at any dose: resulted in death; life threatening required inpatient hospitalization; resulted in persistent, significant disability; was congenital anomaly/birth defect or medically important due to other reasons than mentioned criteria. Number of participants with TEAEs and SAEs were reported.

Time frame:
From the first dose of study drug up to approximately 6 years 3 months
Reported as:
Count of participants · Participants
Phase 2: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
ParticipantsPhase 2: Eribulin Mesylate 1.0 mg/m^2 + Gemcitabine 1000 mg/m^2+ Cisplatin 70 mg/m^2Phase 2: Gemcitabine 1000 mg/m^2+ Cisplatin 70 mg/m^2
TEAEs4138
SAEs2214
SecondaryPhase 2: Progression-free Survival (PFS)

PFS was defined as the time from the date of randomization until the earlier of the following two events: the date of disease progression (PD) or the date of death based on response evaluation criteria in solid tumor (RECIST) version (v) 1.1. PD was defined as at least a 20 percent (%) increase or 5 millimeter (mm) increase in the sum of diameters of target lesions (taking as reference the smallest sum on study) recorded since the treatment started or the appearance of 1 or more new lesions.

Time frame:
From the date of randomization until the earlier of the following two events: the date of PD or the date of death (Up to approximately 6 years 3 months)

No measurements were reported for this outcome.

SecondaryPhase 2: Percentage of Participants With Overall Response

Overall response rate was defined as the percentage of participants with the best confirmed response of complete response (CR) or partial response (PR) based on RECIST v1.1. CR was defined as complete disappearance of all target lesions. Any pathological lymph nodes (whether target or nontarget) must have reduction in short axis to less than 10 mm. PR was defined as at least a 30% decrease in the sum of the longest diameters of target lesions, taking as reference the baseline summed longest diameters.

Time frame:
From the date of randomization until CR or PR (Up to approximately 6 years 3 months)
Reported as:
Number · percentage of participants
Phase 2: Percentage of Participants With Overall Response
percentage of participantsPhase 2: Eribulin Mesylate 1.0 mg/m^2 + Gemcitabine 1000 mg/m^2+ Cisplatin 70 mg/m^2Phase 2: Gemcitabine 1000 mg/m^2+ Cisplatin 70 mg/m^2
Phase 2: Percentage of Participants With Overall Response52.5 (37.0 to 68.0)46.2 (30.5 to 61.8)
SecondaryPhase 2: Percentage of Participants With Progression-free Survival at Week 12

PFS was defined as the time from the date of randomization until the earlier of the following two events: the date of PD or the date of death based on RECIST v1.1. PD was defined as at least a 20% increase or 5 mm increase in the sum of diameters of target lesions (taking as reference the smallest sum on study) recorded since the treatment started or the appearance of 1 or more new lesions.

Time frame:
Week 12

No measurements were reported for this outcome.

SecondaryPhase 2: Time to Progression (TTP)

TTP was defined as the time from the date of randomization until the date of PD based on RECIST v1.1. PD was defined as at least a 20% increase in the sum of the longest diameters of target lesions, taking in reference the smallest summed longest diameters on study (this included the baseline sum if that was the smallest on study). In addition to the relative increase of 20%, the sum must also have demonstrated an absolute increase of at least 5 mm. The appearance of 1 or more new lesions was also considered progression.

Time frame:
From the date of randomization until the date of PD (Up to approximately 6 years 3 months)

No measurements were reported for this outcome.

SecondaryPhase 2: Overall Survival (OS)

OS was defined as the time from the date of randomization until the date of death due to any cause.

Time frame:
From the date of randomization until the date of death (Up to approximately 6 years 3 months)
Reported as:
Median · weeks
Phase 2: Overall Survival (OS)
weeksPhase 2: Eribulin Mesylate 1.0 mg/m^2 + Gemcitabine 1000 mg/m^2+ Cisplatin 70 mg/m^2Phase 2: Gemcitabine 1000 mg/m^2+ Cisplatin 70 mg/m^2
Phase 2: Overall Survival (OS)62.9 (39.86 to 132.0)64.6 (50.43 to 126.4)

Adverse events

Collected over From the first dose of study drug up to approximately 6 years 3 months. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Phase 1b: Eribulin Mesylate 0.7 mg/m^2 + Gemcitabine 1000 mg/m^2+ Cisplatin 70 mg/m^23/3 (100%)0/3 (0%)3/3 (100%)
Phase 1b: Eribulin Mesylate 1.0 mg/m^2 + Gemcitabine 1000 mg/m^2+ Cisplatin 70 mg/m^24/6 (66.7%)1/6 (16.7%)6/6 (100%)
Phase 2: Eribulin Mesylate 1.0 mg/m^2 + Gemcitabine 1000 mg/m^2+ Cisplatin 70 mg/m^222/41 (53.7%)22/41 (53.7%)41/41 (100%)
Phase 2: Gemcitabine 1000 mg/m^2+ Cisplatin 70 mg/m^222/39 (56.4%)14/39 (35.9%)38/39 (97.4%)
Most frequent serious events
Showing 10 of 40
Most frequent serious events
EventPhase 1b: Eribulin Mesylate 0.7 mg/m^2 + Gemcitabine 1000 mg/m^2+ Cisplatin 70 mg/m^2Phase 1b: Eribulin Mesylate 1.0 mg/m^2 + Gemcitabine 1000 mg/m^2+ Cisplatin 70 mg/m^2Phase 2: Eribulin Mesylate 1.0 mg/m^2 + Gemcitabine 1000 mg/m^2+ Cisplatin 70 mg/m^2Phase 2: Gemcitabine 1000 mg/m^2+ Cisplatin 70 mg/m^2
AnaemiaBlood and lymphatic system disorders0/31/62/412/39
AstheniaGeneral disorders0/31/60/410/39
Urinary tract infectionInfections and infestations0/30/62/415/39
Pulmonary EmbolismRespiratory, thoracic and mediastinal disorders0/30/61/414/39
Febrile NeutropeniaBlood and lymphatic system disorders0/30/63/410/39
ThrombocytopeniaBlood and lymphatic system disorders0/30/63/411/39
DiarrhoeaGastrointestinal disorders0/30/63/410/39
HaematuriaRenal and urinary disorders0/30/61/412/39
Deep Vein ThrombosisVascular disorders0/30/62/412/39
NeutropeniaBlood and lymphatic system disorders0/30/62/410/39
Most frequent other events
Showing 10 of 228
Most frequent other events
EventPhase 1b: Eribulin Mesylate 0.7 mg/m^2 + Gemcitabine 1000 mg/m^2+ Cisplatin 70 mg/m^2Phase 1b: Eribulin Mesylate 1.0 mg/m^2 + Gemcitabine 1000 mg/m^2+ Cisplatin 70 mg/m^2Phase 2: Eribulin Mesylate 1.0 mg/m^2 + Gemcitabine 1000 mg/m^2+ Cisplatin 70 mg/m^2Phase 2: Gemcitabine 1000 mg/m^2+ Cisplatin 70 mg/m^2
AnaemiaBlood and lymphatic system disorders3/35/622/4122/39
NeutropeniaBlood and lymphatic system disorders3/33/625/4119/39
ThrombocytopeniaBlood and lymphatic system disorders3/35/618/4114/39
NauseaGastrointestinal disorders3/36/626/4126/39
FatigueGeneral disorders3/35/619/4120/39
Decreased appetiteMetabolism and nutrition disorders2/35/612/4121/39
TinnitusEar and labyrinth disorders2/31/65/418/39
ConstipationGastrointestinal disorders2/32/615/4115/39
AstheniaGeneral disorders2/32/612/4113/39
Oedema peripheralGeneral disorders2/31/64/413/39

Baseline characteristics

SAS included all participants who were randomized and treated in this study.

Age, Categorical
Age, Categorical(Participants)Phase 1b: Eribulin Mesylate 0.7 mg/m^2 + Gemcitabine 1000 mg/m^2 + Cisplatin 70 mg/m^2Phase 1b: Eribulin Mesylate 1.0 mg/m^2 + Gemcitabine 1000 mg/m^2 + Cisplatin 70 mg/m^2Phase 2: Eribulin Mesylate 1.0 mg/m^2 + Gemcitabine 1000 mg/m^2 + Cisplatin 70 mg/m^2Phase 2: Gemcitabine 1000 mg/m^2 + Cisplatin 70 mg/m^2Total
<=18 years00000
Between 18 and 65 years24151435
>=65 years12262554
Sex: Female, Male
Sex: Female, Male(Participants)Phase 1b: Eribulin Mesylate 0.7 mg/m^2 + Gemcitabine 1000 mg/m^2 + Cisplatin 70 mg/m^2Phase 1b: Eribulin Mesylate 1.0 mg/m^2 + Gemcitabine 1000 mg/m^2 + Cisplatin 70 mg/m^2Phase 2: Eribulin Mesylate 1.0 mg/m^2 + Gemcitabine 1000 mg/m^2 + Cisplatin 70 mg/m^2Phase 2: Gemcitabine 1000 mg/m^2 + Cisplatin 70 mg/m^2Total
Female115714
Male25363275
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Phase 1b: Eribulin Mesylate 0.7 mg/m^2 + Gemcitabine 1000 mg/m^2 + Cisplatin 70 mg/m^2Phase 1b: Eribulin Mesylate 1.0 mg/m^2 + Gemcitabine 1000 mg/m^2 + Cisplatin 70 mg/m^2Phase 2: Eribulin Mesylate 1.0 mg/m^2 + Gemcitabine 1000 mg/m^2 + Cisplatin 70 mg/m^2Phase 2: Gemcitabine 1000 mg/m^2 + Cisplatin 70 mg/m^2Total
Hispanic or Latino03238
Not Hispanic or Latino33393479
Unknown or Not Reported00022
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Phase 1b: Eribulin Mesylate 0.7 mg/m^2 + Gemcitabine 1000 mg/m^2 + Cisplatin 70 mg/m^2Phase 1b: Eribulin Mesylate 1.0 mg/m^2 + Gemcitabine 1000 mg/m^2 + Cisplatin 70 mg/m^2Phase 2: Eribulin Mesylate 1.0 mg/m^2 + Gemcitabine 1000 mg/m^2 + Cisplatin 70 mg/m^2Phase 2: Gemcitabine 1000 mg/m^2 + Cisplatin 70 mg/m^2Total
American Indian or Alaska Native00000
Asian00000
Native Hawaiian or Other Pacific Islander00000
Black or African American00000
White36413989
More than one race00000
Unknown or Not Reported00000
08

Study locations

42 sites
  • Birmingham, Alabama 35294, United States
  • Tucson, Arizona 85715, United States
  • Fort Myers, Florida 33916, United States
  • Saint Petersburg, Florida 33705, United States
  • Ann Arbor, Michigan 48109, United States
  • Las Vegas, Nevada 89169, United States
  • East Orange, New Jersey 7018, United States
  • Rochester, New York 55904, United States
  • Chattanooga, Tennessee 37404, United States
  • Fort Worth, Texas 76104, United States
  • Houston, Texas 77024, United States
  • Webster, Texas 77598, United States
  • Huntington, Virginia 25704, United States
  • Northfork, West Virginia 23502, United States
  • Aachen Northwest, 52074, Germany
  • Berlin, Germany
  • Essen, Northwest, 45136, Germany
  • Goch, Northwest, 47574, Germany
  • Hamburg, HH, 20246, Germany
  • Tuebingen, BW, 72076, Germany
  • Wiesbaden, HE, 65191, Germany
  • Maastricht, 6229, Netherlands
  • Nieuwegein, 3435, Netherlands
  • Nijmegen, 6525, Netherlands
  • Barcelona, 8003, Spain
  • Barcelona, 8025, Spain
  • Elche- Alicante, 3203, Spain
  • Madrid, 28034, Spain
  • Madrid, 28040, Spain
  • Madrid, 28050, Spain
  • Sabadell, 8208, Spain
  • Dnipropetrovsk, 49005, Ukraine
  • Dnipropetrovsk, 49102, Ukraine
  • Donetsk, 83092, Ukraine
  • Kharkiv, 61037, Ukraine
  • Kyiv, 3022, Ukraine
  • Lviv, 79031, Ukraine
  • Leicester, United Kingdom
  • Liverpool, United Kingdom
  • London, United Kingdom
  • Manchester, United Kingdom
  • Southampton, United Kingdom
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2010 to primary completion in May 2015, 60 months.

Results were first posted in Feb 2022, 6 years 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 17, 2010
First posted
May 20, 2010
StartActual
Apr 16, 2010
Primary completionActual
May 8, 2015
CompletionActual
Jul 20, 2016
Results first posted
Feb 28, 2022
Last update
Feb 28, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 28, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01126749
Lead sponsor
Eisai Inc.
Collaborators
PharmaBio Development Inc.
Responsible party
Sponsor
First posted
May 20, 2010
Start date
Apr 16, 2010
Primary completion
May 8, 2015
Completion
Jul 20, 2016
Results posted
Feb 28, 2022
Last update
Feb 28, 2022

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jan 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Gemcitabine · Cisplatin

Start the discussion